Oncolytics Biotech (ONCY)
(Delayed Data from NSDQ)
$0.93 USD
-0.03 (-2.92%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.95 +0.02 (2.15%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.93 USD
-0.03 (-2.92%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.95 +0.02 (2.15%) 7:58 PM ET
4-Sell of 5 4
D Value D Growth F Momentum F VGM
Zacks News
Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Oncolytics Biotech (ONCY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.
Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know
by Zacks Equity Research
Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.
Novartis (NVS) to Report Q1 Earnings: What to Expect?
by Ekta Bagri
Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.
After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
New Strong Buy Stocks for January 18th
by Zacks Equity Research
DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.
Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
2 Sector ETFs Hovering Around a 52-Week High
by Sanghamitra Saha
We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.
What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out.
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag
by Zacks Equity Research
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Olink Holding AB publ Sponsored ADR (OLK) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.
Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Oncolytics Biotech Inc. (ONCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech
by Zacks Equity Research
Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.
Ride on Rising P/E Investing With These 5 Top-Ranked Stocks
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).
Oncolytics Biotech (ONCY) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Oncolytics Biotech (ONCY) has been struggling lately, but the selling pressure may be coming to an end soon.
Here's Why Oncolytics Biotech Inc. (ONCY) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Oncolytics Biotech Inc. (ONCY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
5 Stocks With Rising P/E Are Good Buys
by Sanghamitra Saha
Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.
Down 23.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Oncolytics Biotech Inc. (ONCY)
by Zacks Equity Research
Oncolytics Biotech Inc. (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Here's Why Oncolytics Biotech Inc. (ONCY) is Poised for a Turnaround After Losing 19.6% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Oncolytics Biotech (ONCY) Enters Overbought Territory
by Zacks Equity Research
Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company
New Strong Buy Stocks For May 28th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today:
Oncolytics (ONCY) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
During Q4 investors' call, Oncolytics (ONCY) is likely to provide an update on the studies of pelareorep, which is being developed for treating solid tumors and hematological malignancies.
Repligen (RGEN) Stock Down Despite Q4 Earnings & Sales Beat
by Zacks Equity Research
Repligen's (RGEN) beats on both earnings and revenues in Q4. However, stock declines.
Trevena (TRVN) Resubmits NDA for Pain Drug Oliceridine to FDA
by Zacks Equity Research
Trevena (TRVN) resubmits the NDA to the FDA for IV oliceridine for the management of moderate-to-severe acute pain.